News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
AOL.com Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Mizuho has reiterated an Outperform rating and $19.00 price target for Relmada Therapeutics Inc (NASDAQ:RLMD) despite concerns over manufacturing delays for its NDV-01 program. The stock has seen a significant decline since these concerns emerged, though it has surged over 700% in the past …
Relmada Therapeutics (NASDAQ:RLMD) announced its quarterly earnings, reporting an EPS loss of $0.11, significantly beating analysts' expectations of a $0.20 loss by $0.09. Despite the positive earnings surprise and a strong financial position with $217.7 million in cash expected to fund operations through 2029, …
Piper Sandler analyst Kelsey Goodwin maintained a Buy rating on Relmada Therapeutics (RLMD) with a price target of $12.00, noting Goodwin's strong track record in the Healthcare sector. H.C. Wainwright also reiterated a Buy rating and a $12.00 price target for the stock. Relmada …
RELMADA THERAPEUTICS, INC. reported a net loss of $12.9 million and a diluted loss per share of $0.11 for the second quarter of 2026. This widened loss compared to the previous year is attributed to increased R&D and manufacturing spending to advance its pipeline. …
Relmada Therapeutics announced its second quarter 2026 financial results and provided a business update. The report details the company's financial performance during this period and outlines key developments in its business operations. This release offers stakeholders insight into Relmada's recent progress and future outlook.
Relmada Therapeutics Inc (RLMD) reported strong Phase 2 data for NDVO1 and has FDA alignment on registrational pathways. Despite a strong balance sheet and plans for IND filings by the end of 2026, the company faces delays in NDVO1 IND filing due to manufacturing …
Relmada Therapeutics reported a wider net loss of $12.9 million in Q2 2026, despite a narrowed GAAP loss per share, driven by a nearly threefold increase in R&D expenses to $8.4 million. The company is prioritizing manufacturing and regulatory preparations for its NDV-01 and …
Relmada Therapeutics reported a narrower-than-expected Q2 2026 loss of $0.11 per share, beating analyst estimates, but its shares fell due to investor focus on drug development timelines and higher research spending. The company's lead drug, NDV-01 for bladder cancer, and sepranolone for Prader-Willi syndrome, …
Relmada Therapeutics reported a net loss of $12.9 million for Q2 2026, alongside a business update on its oncology and CNS pipeline. The company is advancing its lead candidate, NDV-01, for non-muscle invasive bladder cancer towards a Phase 3 registrational program, with an IND …
This article reports on the filing of a Form 8K by Relmada Therapeutics Inc. on August 6th. The content is brief and serves primarily as an announcement of this regulatory filing, likely containing important company updates.
Relmada Therapeutics has announced the appointment of Bipin Dalmia as its new Chief Business Officer. In this role, Dalmia will be responsible for leading business development strategies to advance the company's lead asset, NDV-01, and drive overall corporate growth. His appointment is expected to …
Janus Henderson Group PLC significantly increased its stake in Relmada Therapeutics (NASDAQ:RLMD) by 52.2% in the first quarter, now owning over 11 million shares, representing 10.55% of the company. Institutional investors collectively hold 45.24% of RLMD, and analysts have a "Moderate Buy" rating with …
Relmada Therapeutics Inc (RLMD) currently holds a financial score of 5.49, placing it low within the Biotechnology & Medical Research industry, reflecting weak financial status and low operating efficiency. The report indicates that the company has not yet disclosed relevant data for several key …
Relmada Therapeutics, Inc. has appointed Bipin Dalmia as its new Chief Business Officer. Dalmia brings nearly 30 years of biopharmaceutical experience, having previously led portfolio strategy and business development at Ferring Pharmaceuticals, where he also played a key role in the U.S. launch of …
Relmada Therapeutics has appointed Bipin Dalmia as its new Chief Business Officer, reporting directly to CEO Sergio Traversa. Dalmia will be responsible for leading corporate strategy, commercial planning, and business development, specifically focusing on the late-stage development of NDV-01. This appointment highlights Relmada's commitment …
Relmada Therapeutics, Inc. has appointed Bipin Dalmia as its new Chief Business Officer. Dalmia, who brings nearly 30 years of biopharmaceutical experience, will be responsible for leading the company’s corporate strategy, commercial planning, and business development initiatives. He previously served at Ferring Pharmaceuticals, where …
Relmada Therapeutics (Nasdaq: RLMD) has appointed Bipin Dalmia, PhD, MBA, as its Chief Business Officer. Dalmia brings nearly 30 years of biopharmaceutical leadership, including experience leading the Uro-Oncology Franchise and the U.S. launch of ADSTILADRIN, the first FDA-approved intravesical gene therapy for BCG-unresponsive non-muscle …
Relmada Therapeutics has appointed Bipin Dalmia, PhD, MBA, as its new Chief Business Officer. Dalmia brings nearly three decades of experience in biopharmaceutical leadership, corporate strategy, and business development, with a focus on uro-oncology, which will be crucial as Relmada advances its NMIBC therapy, …
This article from TradingKey discusses the revenue breakdown of Relmada Therapeutics Inc (RLMD), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It provides current stock information for RLMD, including its trading price, …
This article provides an overview of Relmada Therapeutics Inc (RLMD) including its current stock price, market cap, and a section dedicated to its dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past 5 years. The …
This article provides a detailed breakdown of Relmada Therapeutics Inc's (RLMD) shareholder structure, listing major shareholders and their respective proportions. It also categorizes shareholders by type, such as investment advisors, hedge funds, and individual investors. Additionally, the article presents institutional shareholding data over various …
This article provides a company profile for Relmada Therapeutics Inc (FWB:4E2) on the Frankfurt Stock Exchange. It highlights the availability of financial data, segments, and other market information for the pharmaceutical company through TradingView. The page serves as a hub for investors to access …
This article provides a detailed financial overview of Relmada Therapeutics Inc. (RLMD), presenting key financial statements including income, balance sheet, and cash flow data. It highlights current stock performance, upcoming earnings dates, and analyst ratings, offering a comprehensive look at the company's financial health …
This article provides a risk assessment for Relmada Therapeutics Inc (RLMD), focusing on its volatility, financial risk, and investment risk. The company has a current risk assessment score of 1.94, ranking 251 out of 386 in the Biotechnology & Medical Research industry, indicating it …
The institutional confidence score for Relmada Therapeutics Inc (RLMD) is 5.00, placing it 132nd out of 386 in the Biotechnology & Medical Research industry. Institutional shareholding stands at 56.47%, marking a significant quarter-over-quarter increase of 184.86%. Steven Cohen is the largest institutional shareholder with …
Relmada Therapeutics has scheduled its Q2 2026 financial results conference call for August 6, 2026, at 4:30 p.m. ET. A webcast of the call will be available at the provided link. This news brief was generated by Public Technologies using AI based on content …
Relmada Therapeutics, Inc. is scheduled to host a conference call and webcast on August 6, 2026, at 4:30 PM ET to discuss its financial results for the second quarter ended June 30, 2026. The clinical-stage biotechnology company will also provide updates on its recent …
Relmada Therapeutics (Nasdaq: RLMD) will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 PM ET to discuss its financial results for the second quarter ended June 30, 2026, and provide a business update. Investors can join the call via …
Search by ticker symbol or company name and select a result to open its chart.